Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

SipD and IpaD induce a cross-protection against Shigella and Salmonella infections.

Tytuł:
SipD and IpaD induce a cross-protection against Shigella and Salmonella infections.
Autorzy:
Jneid B; Université Paris Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, Gif-sur-Yvette, France.
Rouaix A; Université Paris Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, Gif-sur-Yvette, France.
Féraudet-Tarisse C; Université Paris Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, Gif-sur-Yvette, France.
Simon S; Université Paris Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, Gif-sur-Yvette, France.
Źródło:
PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2020 May 28; Vol. 14 (5), pp. e0008326. Date of Electronic Publication: 2020 May 28 (Print Publication: 2020).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: San Francisco, CA : Public Library of Science
MeSH Terms:
Cross Protection*
Antigens, Bacterial/*immunology
Bacterial Proteins/*immunology
Dysentery, Bacillary/*prevention & control
Membrane Proteins/*immunology
Salmonella Infections/*prevention & control
Salmonella Vaccines/*immunology
Shigella Vaccines/*immunology
Administration, Intranasal ; Administration, Oral ; Animals ; Antibodies, Bacterial/analysis ; Disease Models, Animal ; Female ; Immunoglobulin A/analysis ; Immunoglobulin G/analysis ; Mice, Inbred BALB C ; Salmonella Vaccines/administration & dosage ; Salmonella typhimurium/immunology ; Shigella Vaccines/administration & dosage ; Shigella flexneri/immunology ; Survival Analysis
References:
Infect Immun. 2012 Mar;80(3):1222-31. (PMID: 22202122)
Infect Immun. 2018 Feb 20;86(3):. (PMID: 29311233)
Expert Rev Vaccines. 2009 Dec;8(12):1693-704. (PMID: 19943764)
BMC Genomics. 2011 Aug 25;12:433. (PMID: 21867535)
Infect Immun. 1995 May;63(5):1947-54. (PMID: 7729907)
Vaccine. 2016 Jun 3;34(26):2907-2910. (PMID: 27032517)
Nat Rev Microbiol. 2017 Jun;15(6):323-337. (PMID: 28392566)
Clin Infect Dis. 2012 Dec;55 Suppl 4:S215-24. (PMID: 23169934)
PLoS One. 2012;7(7):e40404. (PMID: 22815747)
J Clin Microbiol. 1993 Feb;31(2):454-7. (PMID: 8432838)
Biochim Biophys Acta. 2014 Aug;1843(8):1649-63. (PMID: 24512838)
Immunol Cell Biol. 2007 Feb-Mar;85(2):119-29. (PMID: 17213832)
Infect Immun. 2000 Jun;68(6):3344-8. (PMID: 10816483)
Hum Vaccin Immunother. 2014;10(6):1478-93. (PMID: 24804797)
Vaccine. 2011 Sep 16;29(40):7009-19. (PMID: 21787825)
Infect Immun. 2008 Sep;76(9):4137-44. (PMID: 18625740)
Annu Rev Cell Dev Biol. 2001;17:53-86. (PMID: 11687484)
J Clin Invest. 2008 Apr;118(4):1553-62. (PMID: 18357343)
Emerg Infect Dis. 2015 Jun;21(6):. (PMID: 25860298)
Microbiologyopen. 2012 Sep;1(3):243-58. (PMID: 23170225)
Curr Top Microbiol Immunol. 2009;337:231-55. (PMID: 19812985)
Clin Immunol. 2011 May;139(2):185-92. (PMID: 21388888)
Infect Immun. 2010 Aug;78(8):3369-77. (PMID: 20515933)
Front Cell Infect Microbiol. 2016 Mar 09;6:28. (PMID: 27014638)
Front Microbiol. 2011 Jul 04;2:142. (PMID: 21772833)
Am J Trop Med Hyg. 2002 Nov;67(5):533-8. (PMID: 12479558)
Nat Rev Microbiol. 2007 Jul;5(7):540-53. (PMID: 17558427)
Front Immunol. 2015 May 07;6:219. (PMID: 25999954)
Emerg Infect Dis. 1999 Mar-Apr;5(2):216-23. (PMID: 10221873)
mSphere. 2018 Aug 1;3(4):. (PMID: 30068560)
Immunol Lett. 2017 Oct;190:42-50. (PMID: 28720334)
Mol Microbiol. 1992 Nov;6(21):3077-87. (PMID: 1360615)
Clin Vaccine Immunol. 2016 Dec 5;23(12):904-907. (PMID: 27707764)
PLoS Negl Trop Dis. 2016 Dec 19;10(12):e0005207. (PMID: 27992422)
Clin Infect Dis. 2012 Dec;55 Suppl 4:S225-31. (PMID: 23169935)
Lancet Infect Dis. 2017 Sep;17(9):909-948. (PMID: 28579426)
Curr Opin Microbiol. 2009 Feb;12(1):110-6. (PMID: 19157960)
Lancet. 2018 Feb 24;391(10122):801-812. (PMID: 29254859)
Pediatr Infect Dis J. 2013 Mar;32(3):217-21. (PMID: 23249909)
Hum Vaccin. 2007 Nov-Dec;3(6):268-75. (PMID: 17938573)
Clin Infect Dis. 2014 Oct;59(7):933-41. (PMID: 24958238)
PLoS Pathog. 2013 Mar;9(3):e1003245. (PMID: 23555258)
Vaccine. 2013 Jun 19;31(28):2919-29. (PMID: 23644075)
EBioMedicine. 2017 Aug;22:164-172. (PMID: 28735965)
Lancet. 2013 Jul 20;382(9888):209-22. (PMID: 23680352)
Vaccine. 2015 Jun 19;33 Suppl 3:C36-41. (PMID: 25902362)
Clin Vaccine Immunol. 2017 Feb 6;24(2):. (PMID: 27927680)
Curr Opin Microbiol. 2000 Feb;3(1):54-9. (PMID: 10679413)
Biochem Pharmacol. 1961 Jul;7:88-95. (PMID: 13726518)
Immunol Rev. 2011 Mar;240(1):196-210. (PMID: 21349095)
PLoS One. 2012;7(1):e29151. (PMID: 22235266)
PLoS Pathog. 2006 Feb;2(2):e11. (PMID: 16518469)
Vaccine. 2009 Jan 22;27(4):565-72. (PMID: 19022324)
Am J Trop Med Hyg. 2012 Feb;86(2):246-253. (PMID: 22302857)
Infect Immun. 1992 May;60(5):1786-92. (PMID: 1373399)
J Infect Dis. 1992 Jul;166(1):158-61. (PMID: 1607690)
Infect Immun. 1991 Jul;59(7):2341-50. (PMID: 2050402)
Travel Med Infect Dis. 2015 Jul-Aug;13(4):285-94. (PMID: 26026478)
J Exp Med. 1995 Sep 1;182(3):769-78. (PMID: 7544397)
J Pharm Sci. 2010 Nov;99(11):4497-509. (PMID: 20845449)
JAMA. 1997 Aug 6;278(5):389-95. (PMID: 9244330)
Infect Immun. 1998 Oct;66(10):4579-87. (PMID: 9746553)
Expert Rev Vaccines. 2006 Oct;5(5):669-86. (PMID: 17181440)
Substance Nomenclature:
0 (Antibodies, Bacterial)
0 (Antigens, Bacterial)
0 (Bacterial Proteins)
0 (Immunoglobulin A)
0 (Immunoglobulin G)
0 (IpaD protein, Shigella flexneri)
0 (Membrane Proteins)
0 (Salmonella Vaccines)
0 (Shigella Vaccines)
0 (SspD protein, Salmonella typhimurium)
Entry Date(s):
Date Created: 20200529 Date Completed: 20200721 Latest Revision: 20200721
Update Code:
20240105
PubMed Central ID:
PMC7282677
DOI:
10.1371/journal.pntd.0008326
PMID:
32463817
Czasopismo naukowe
Salmonella and Shigella species are food- and water-borne pathogens that are responsible for enteric infections in both humans and animals and are still the major cause of morbidity and mortality in the emerging countries. The existence of multiple Salmonella and Shigella serotypes as well as the emergence of strains resistant to antibiotics require the development of broadly protective therapies. Those bacteria utilize a Type III Secretion System (T3SS), necessary for their pathogenicity. The structural proteins composing the T3SS are common to all virulent Salmonella and Shigella spp., particularly the needle-tip proteins SipD (Salmonella) and IpaD (Shigella). We investigated the immunogenicity and protective efficacy of SipD and IpaD administered by intranasal and intragastric routes, in a mouse model of Salmonella enterica serotype Typhimurium (S. Typhimurium) intestinal challenge. Robust IgG (in all immunization routes) and IgA (in intranasal and oral immunization routes) antibody responses were induced against both proteins. Mice immunized with SipD or IpaD were protected against lethal intestinal challenge with S. Typhimurium or Shigella flexneri (100 Lethal Dose 50%). We have shown that SipD and IpaD are able to induce a cross-protection in a murine model of infection by Salmonella and Shigella. We provide the first demonstration that Salmonella and Shigella T3SS SipD and IpaD are promising antigens for the development of a cross-protective Salmonella-Shigella vaccine. These results open the way to the development of cross-protective therapeutic molecules.
Competing Interests: The authors have declared that no competing interests exist.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies